C225 Inactivation of over-expressed wild type EGFR by Cetuximab recombinant antibody Authored: Orlic-Milacic, M, 2011-11-04 Cetuximab binds to the extracellular domain of EGFR and blocks ligand binding, leading to receptor inactivation, internalization and degradation. Cetuximab is approved for combination therapy and monotherapy of metastatic colorectal cancer and advanced squamous cell carcinoma of head and neck in patients whose tumors over-express wild-type EGFR protein, usually due to amplification of EGFR gene. Edited: D'Eustachio, P, 2011-11-07 Edited: Matthews, L, 2011-11-07 Edited: Wu, G, 2011-11-07 Pubmed15269313 Pubmed15837620 Pubmed16314626 Reactome Database ID Release 431248677 Reactome, http://www.reactome.org ReactomeREACT_115741 Reviewed: Greulich, H, 2011-11-15 Reviewed: Savas, S, 2011-11-15 EGFR:Cetuximab